AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0016
Drug name and formulations:	Utrogestan 100mg oral capsules (progesterone)

Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	No concerns on safety
Clinical effectiveness	*Established licensed product*	No differential between peer group
Strength of evidence		Weak evidence
Cost effectiveness or resource impact	*£*	Small impact per patient but moderate impact at population level.
Place of therapy relative to available treatments	*1/2nd tier*	Third or fourth line
National guidance and priorities	*NICE, MTRAC*	SMC has declined this agent
Local health priorities	*CCG views*	Likely to be low priority
Equity of access	*Equality assessment*	There are other options if this product was not available. No impact if applied to all groups equally. Current patients would continue as the formulary is for new patients.
Stakeholder views	*Define wider groups to be engaged*	No groups identified
Implementation requirements	*Requires, RICAD ESCA etc.*	No RICaD or ESCA would be required

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	The APC were of the view that Green was not appropriate given the cost and the potential for creating wider use of a product that has a smaller place. It may be more appropriate as Amber with a defined place for the therapy. It was agreed that AP would contact LR to review the application and develop a clearer protocol. The APC decision was deferred.

Not approved and rationale:	
Formulary status (RAG) and rationale	
Implementation requirements:	A decision tree was deemed necessary
Implementation monitoring:	